ERCC1 and gastric cancer: For example, it has been reported that high ERCC1 expression is associated with significant tumor reduction and prolonged survival in patients with GC receiving CDDP and fluorouracil (5-FU) (FP) [17]; 5-FU, folinic acid, and oxaliplatin (FOLFOX) therapy [18]; and docetaxel, CDDP, and S-1 (DCS) [20] as neoadjuvant chemotherapy regimens.